- Conditions
- HIV Infections
- Interventions
- PGT121.414.LS, VRC07-523LS
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 961
matching trials from the live ClinicalTrials.gov search.
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
- Interventions
- TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more
- Conditions
- Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
- Interventions
- VP-001
- Drug
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more
- Conditions
- Anemia, Iron-Deficiency
- Interventions
- CSJ137, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- San Diego, California • Lakewood, Colorado • Orlando, Florida + 2 more
- Conditions
- Healthy
- Interventions
- PF-04958242, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic, Chronic
- Interventions
- PCI-24781
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Greenbrae, California • Chicago, Illinois • Nashville, Tennessee + 1 more
- Conditions
- Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
- Interventions
- OT-82 Dose Escalation, OT-82 Dose Expansion
- Drug
- Lead sponsor
- Oncotartis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Duarte, California • Miami, Florida + 5 more
- Conditions
- Infections, Bacterial
- Interventions
- GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- SCLC
- Interventions
- ZL-1310, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Duarte, California • New Haven, Connecticut • Sarasota, Florida + 8 more
- Conditions
- Tumor, Solid
- Interventions
- BDB018, Pembrolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas
- Conditions
- Phenylketonurias, PAH Deficiency
- Interventions
- HMI-102
- Genetic
- Lead sponsor
- Homology Medicines, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Orange, California • Tampa, Florida + 10 more
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)
- Drug
- Lead sponsor
- Oncomatryx Biopharma S.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mycosis Fungoides, Sezary Syndrome
- Interventions
- HuMax-CD4 (zanolimumab)
- Drug
- Lead sponsor
- Emergent Product Development Seattle LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 15 more
- Conditions
- Mesothelioma
- Interventions
- LMB-100, nab-paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Oropharyngeal Neoplasms
- Interventions
- Intensity-modulated radiation therapy (IMRT), Cisplatin
- Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • St Louis, Missouri
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Interventions
- Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
- Drug
- Lead sponsor
- Benjamin T Diamond, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Interventions
- Alemtuzumab
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 7
- States / cities
- La Jolla, California • La Verne, California • Aurora, Colorado + 4 more
- Conditions
- Malignant Melanoma
- Interventions
- Decitabine, Temozolomide, biopsy
- Drug · Procedure
- Lead sponsor
- Hussein Tawbi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- NSCLC
- Interventions
- Tarceva
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Bakersfield, California • Winston-Salem, North Carolina
- Conditions
- Advanced Solid Tumor
- Interventions
- SNV1521, DB-1310, Abiraterone, Darolutamide
- Drug
- Lead sponsor
- ParVation Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Columbus, Ohio
- Conditions
- Melanoma, Lung Cancer
- Interventions
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neoplasms
- Interventions
- FdCyd + THU
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 6
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 3 more
- Conditions
- Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
- Interventions
- Obrixtamig - parenteral 1, Obrixtamig - parenteral 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more